<DOC>
	<DOCNO>NCT02052960</DOCNO>
	<brief_summary>The aim study evaluate efficacy CetuGEX™ treatment patient stage III/IV recurrent and/or metastatic SCCHN compare cetuximab ( combination platinum-based chemotherapy ) term progression-free survival ( PFS ) .</brief_summary>
	<brief_title>CetuGEX™ Comparison Cetuximab Treatment Patients With Head Neck Cancer</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Squamous Cell</mesh_term>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<criteria>1 . Patients histologically confirm recurrent and/or metastatic EGFRpositive SCCHN eligible local treatment . 2 . Patients measurable disease accord Response Evaluation Criteria Solid Tumors ( RECIST ) 1.1 . 3 . Patients age least 18 year screen . 4 . Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 . 5 . Minimum life expectancy 3 month . 6 . Tissue sample available specific disease therapy related biological assessment . 7 . If female childbearing potential , nonlactating negative pregnancy test result screen prior randomization . 8 . If female , either childbearing potential use highly effective contraceptive . 9 . Willing able comply protocol . 10 . Willing able provide write informed consent . 1 . Prior systemic chemotherapy ( except give part multimodal treatment locally advanced disease complete 6 month prior screen ) . 2 . Cetuximab EGFR target agent treatment ( except give part multimodal treatment locally advanced disease complete 6 month prior screen ) . 3 . Surgery ( minor intervention like diagnostic biopsy intravenous port implantation ) irradiation within 30 day randomization . 4 . Concomitant antitumor therapy concomitant immunotherapy . 5 . Concomitant corticosteroid treatment unless specify within protocol . 6 . Clinical evidence brain metastasis leptomeningeal involvement . 7 . Patients nasopharyngeal tumor . 8 . Concomitant malignant disease , except adequately treat tumor high likelihood cure ( e.g. , basal cell cancer skin , cervical cancer breast cancer situ ) . Patients previous malignancy without evidence disease least 5 year allow enter study . 9 . Patients renal hepatic impairment . 10 . Clinically active infection ≥ Grade 2 use National Cancer Institute ( NCI ) Common Terminology Criteria Adverse Events ( CTCAE ) version 4 and/or require intravenous antibiotic . 11 . Known active hepatitis B C. 12 . Known human immunodeficiency virus ( HIV ) infection . 13 . Myocardial infarction within 6 month prior screen . 14 . Symptomatic congestive heart failure ( New York Heart Association [ NYHA ] Grade 3 4 ) , unstable angina pectoris within 6 month prior screen , significant cardiac arrhythmia , history stroke transient ischemic attack within 1 year prior screen . 15 . History keratitis require medical intervention within last 5 year . 16 . Patients disorder , opinion investigator , might interfere conduct study . 17 . Patients unstable condition ( e.g. , psychiatric disorder , recent history drug alcohol abuse , interfere study compliance , within 6 month prior screen ) otherwise think unreliable incapable complying requirement protocol . 18 . Patients institutionalized official mean court order . 19 . Receipt investigational medicinal product within last 30 day randomization previous CetuGEX™ administration . 20 . Prior allergic reaction monoclonal antibody , grade 3 infusion relate reaction ( IRR ) grade 4 reaction monoclonal antibody . 21 . Known sensitivity component investigational medicinal product ( IMP ) medication use study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>